资讯
Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...
HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection that required minimal preparation NEW YORK-- (BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive ...
You may report side effects to the FDA at 1-800-FDA-1088. The full Prescribing Information can be found here. About Pfizer: Breakthroughs That Change Patients’ Lives ...
Hympavzi's closest counterpart in the TFPI category is Novo Nordisk's concizumab, which was turned down by the FDA last year due to manufacturing issues.
Pfizer Inc. announced positive topline results from the phase 3 BASIS study (NCT03938792) evaluating Hympavzi (marstacimab) for adults and adolescents living with haemophilia A or B with inhibitors.
Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果